Talk:C-Met inhibitor
Latest comment: 7 years ago by Rod57 in topic tivantinib 'conflict'
| This is the talk page for discussing improvements to the C-Met inhibitor article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about C-Met inhibitor.
|
original name edit
Until April 2012 this article was Discovery and development of small molecule c-Met inhibitors
chlorine placed wrong in structure edit
There is small error in the structure of SU11274: chlorine should be in meta-position, not para in the phenyl ring. Stereochemistry in the chiral pyrrolidine ring of structure of PHA-665752 is not shown. — Preceding unsigned comment added by Tanevala (talk • contribs) 06:45, 5 October 2011 (UTC)
Any updates for 2012 edit
Article doesn't seem to use any 2012 sources so the status of clinical trials may be out of date now. - Rod57 (talk) 00:22, 19 December 2012 (UTC)
tivantinib 'conflict' edit
Actually there is more detail here than in tivantinib so perhaps the detail should be moved there. - Rod57 (talk) 19:36, 20 February 2017 (UTC)